Epizyme (EPZM) Received its Third Buy in a Row


After Citigroup and H.C. Wainwright gave Epizyme (NASDAQ: EPZM) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Yaron Werber maintained a Buy rating on Epizyme today and set a price target of $18. The company’s shares opened today at $13.67, close to its 52-week high of $15.15.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 13.0% and a 63.6% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.

Currently, the analyst consensus on Epizyme is a Strong Buy with an average price target of $22.67, implying a 65.8% upside from current levels. In a report issued on June 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $25 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.15 and a one-year low of $5.14. Currently, Epizyme has an average volume of 762.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts